Table 1—

Baseline health-related quality of life in the all-treated population, assessed using two instruments#

BosentanPlacebo
SGRQ
 Symptoms components51.2 (44.7–56.0)54.8 (47.9–59.1)+
 Activity components59.5 (53.6–66.1)§59.5 (56.0–65.6)ƒ
 Impacts components32.9 (25.0–40.3)§30.5 (25.7–38.4)##
 Total score43.9 (36.6–52.1)¶¶44.3 (40.2–50.0)++
SF-36
 Physical functioning55.0 (40.0–65.0)47.5 (35.0–55.0)+
 Role physical25.0 (25.0–50.0)§25.0 (25.0–50.0)##
 Bodily pain74.0 (64.0–100.0)64.0 (61.0–74.0)+
 Social functioning75.0 (75.0–87.5)81.3 (62.5–87.5)+
 Mental health80.0 (68.0–84.0)§76.0 (68.0–80.0)+
 Role emotional100.0 (66.7–100.0)100.0 (66.7–100.0)##
 Vitality50.0 (40.0–55.0)§50.0 (40.0–55.0)+
 General health47.0 (37.0–57.0)46.0 (40.0–52.0)+
  • Data are presented as median (95% confidence interval). These data show that the patients in the two groups were similarly impaired at baseline. SGRQ: St George’s Respiratory Questionnaire; SF-36: 36-item short-form health survey. #: SGRQ and SF-36; : n = 68; +: n = 82; §: n = 67; ƒ: n = 83; ##: n = 81; ¶¶: n = 66; ++: n = 80.